Skip To Main Content

Venetoclax (BCL-2 inhibitor)

(RG7601, ABT-199)

Hematology

Phase III

A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (CANOVA)

NCT03539744

Phase II

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)

NCT02899052